Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 27 July 1979:
Vol. 205. no. 4404, pp. 408 - 410
DOI: 10.1126/science.377491
Prev | Table of Contents | Next

Articles

Science, Vol 205, Issue 4404, 408-410
Copyright © 1979 by American Association for the Advancement of Science

articles

Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor

RF Casper and SS Yen

Subcutaneous injection of 50 micrograms of a long-acting analog of luteinizing hormone-releasing factor on each of two successive days during mid-luteal phase in normally cycling women induced a short luteal phase and premature menstruation. These events were associated with luteolysis, as evidenced by the consistent and parallel premature decline of progesterone and estradiol levels compared with those in control cycles. This finding may prove to be useful in the prevention or interception of implantation.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
GnRHa to trigger final oocyte maturation: a time to reconsider.
P. Humaidan, E.G. Papanikolaou, and B.C. Tarlatzis (2009)
Hum. Reprod. 24, 2389-2394
   Abstract »    Full Text »    PDF »
An update of luteal phase support in stimulated IVF cycles.
H.M. Fatemi, B. Popovic-Todorovic, E. Papanikolaou, P. Donoso, and P. Devroey (2007)
Hum. Reprod. Update 13, 581-590
   Abstract »    Full Text »    PDF »
The early luteal phase administration of estrogen and progesterone does not induce premature luteolysis in normo-ovulatory women..
N. G M Beckers, P. Platteau, M. J Eijkemans, N. S Macklon, F. H de Jong, P. Devroey, and B. C J M Fauser (2006)
Eur. J. Endocrinol. 155, 355-363
   Abstract »    Full Text »    PDF »
Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study.
L. Dal Prato, A. Borini, G. Coticchio, M. Cattoli, and C. Flamigni (2004)
Hum. Reprod. 19, 2200-2205
   Abstract »    Full Text »    PDF »
Action of Gonadotropin-Releasing Hormone II on the Baboon Ovary.
T. M. Siler-Khodr, M. Grayson, and C. A. Eddy (2003)
Biol Reprod 68, 1150-1156
   Abstract »    Full Text »    PDF »
Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
G. Ragni, W. Vegetti, E. Baroni, M. Colombo, M. Arnoldi, G. Lombroso, and P. G. Crosignani (2001)
Hum. Reprod. 16, 2258-2262
   Abstract »    Full Text »    PDF »
Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study.
L.D. Prato, A. Borini, M.R. Trevisi, M.A. Bonu, E. Sereni, and C. Flamigni (2001)
Hum. Reprod. 16, 1409-1414
   Abstract »    Full Text »    PDF »
Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix.
A. Tavaniotou, C. Albano, J. Smitz, and P. Devroey (2001)
Hum. Reprod. 16, 663-667
   Abstract »    Full Text »    PDF »
Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles.
C. Albano, J. Smitz, H. Tournaye, H. Riethmuller-Winzen, A. Van Steirteghem, and P. Devroey (1999)
Hum. Reprod. 14, 1426-1430
   Abstract »    Full Text »    PDF »
Luteal phase defects induced by an agonist of luteinizing hormone-releasing factor: a model for fertility control.
K. Sheehan, R. Casper, and S. Yen (1982)
Science 215, 170-172
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)